Seeking Alpha

The FDA has approved Teva's (TEVA -0.6%) Synribo to treat adults with chronic myelogenous...

The FDA has approved Teva's (TEVA -0.6%) Synribo to treat adults with chronic myelogenous leukemia, a blood and bone marrow disease. The drug is intended to be used in patients whose cancer progressed after treatment with at least two drugs from a class called tyrosine kinase inhibitors, also used to treat the disease.
Comments (2)
  • doc47
    , contributor
    Comments (992) | Send Message
     
    Given the market reaction: So what!?
    26 Oct 2012, 11:34 AM Reply Like
  • luhen
    , contributor
    Comments (77) | Send Message
     
    Can anybody explain the behavior of Teva's equity ???
    26 Oct 2012, 12:28 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|